A phase II trial of SU5416 (NSC 696819) [semaxanib] in patients with metastatic melanoma
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Semaxanib (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 23 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 24 Sep 2005 New trial record.